436 related articles for article (PubMed ID: 30334460)
21. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
Muchtar E; Magen H; Gertz MA
Leuk Lymphoma; 2017 Jun; 58(6):1283-1296. PubMed ID: 27734720
[TBL] [Abstract][Full Text] [Related]
22. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
23. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.
Moulopoulos LA; Dimopoulos MA; Kastritis E; Christoulas D; Gkotzamanidou M; Roussou M; Koureas A; Migkou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Gika D; Koutoulidis V; Terpos E
Am J Hematol; 2012 Sep; 87(9):861-4. PubMed ID: 22641455
[TBL] [Abstract][Full Text] [Related]
24. The clonal evolution during long-term clinical course of multiple myeloma.
Mishima Y; Mishima Y; Shirouchi Y; Nishimura N; Yokoyama M; Okabe T; Inoue N; Uryu H; Fukuta T; Hatake K; Terui Y
Int J Hematol; 2021 Feb; 113(2):279-284. PubMed ID: 32864713
[TBL] [Abstract][Full Text] [Related]
25. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
26. Towards Stratified Medicine in Plasma Cell Myeloma.
Egan P; Drain S; Conway C; Bjourson AJ; Alexander HD
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775669
[TBL] [Abstract][Full Text] [Related]
27. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
28. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
[No Abstract] [Full Text] [Related]
29. The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI; Milani P; Derudas D; Buadi FK
Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
[TBL] [Abstract][Full Text] [Related]
30. [Updated criteria for diagnosis and risk stratification in patients with multiple myeloma].
Djurdjević P; Andjelković N; Bila J
Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():95-102. PubMed ID: 22352190
[TBL] [Abstract][Full Text] [Related]
31. Multiple Myeloma Genomics - A Concise Review.
Castaneda O; Baz R
Acta Med Acad; 2019 Apr; 48(1):57-67. PubMed ID: 31264433
[TBL] [Abstract][Full Text] [Related]
32. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R; Barlogie B; Haessler J; Tricot G; Anaissie E; Shaughnessy JD; Epstein J; van Hemert R; Erdem E; Hoering A; Crowley J; Ferris E; Hollmig K; van Rhee F; Zangari M; Pineda-Roman M; Mohiuddin A; Yaccoby S; Sawyer J; Angtuaco EJ
J Clin Oncol; 2007 Mar; 25(9):1121-8. PubMed ID: 17296972
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
34. Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.
Avet-Loiseau H; Facon T
Leukemia; 2018 Jun; 32(6):1267-1276. PubMed ID: 29720731
[TBL] [Abstract][Full Text] [Related]
35. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
36. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
[TBL] [Abstract][Full Text] [Related]
37. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.
Sawyer JR; Tian E; Shaughnessy JD; Epstein J; Swanson CM; Stangeby C; Hale CL; Parr L; Lynn M; Sammartino G; Lukacs JL; Stein C; Bailey C; Zangari M; Davies FE; Van Rhee F; Barlogie B; Morgan GJ
Leukemia; 2017 Mar; 31(3):637-644. PubMed ID: 27694925
[TBL] [Abstract][Full Text] [Related]
38. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
39. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]